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Essentials
 The RIETE-VTE score predicts 30-day mortality in cancer-associated venous 
thromboembolism (VTE)
 We externally validated the RIETE-VTE score and compared its accuracy to the 
modified Ottawa score
 Both scores accurately identified low-risk patients for 30-day mortality
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Abstract
Background: The RIETE-VTE score was derived to risk-stratify patients with cancer-
associated venous thromboembolism (CAT).
Objectives: To externally validate the RIETE-VTE score and to compare its prognostic 
performance with the modified Ottawa score.
Patients/Methods: We studied 178 elderly patients with CAT in a prospective 
multicenter cohort and assessed 30-day all-cause mortality, 90-day overall complications 
(mortality, major bleeding, or venous thromboembolism [VTE] recurrence), and 6-month 
VTE recurrence. Patients were stratified into RIETE-VTE and modified Ottawa score risk 
classes (low, intermediate, high). We compared the discriminative power (area under the 
receiver operating characteristics [ROC] curve) to predict mortality, overall complications, 
and VTE recurrence.
Results: Fifteen patients (8.4%) died within 30 days, 42 (23.6%) experienced an overall 
complication by day 90, and 6 (3.4%) had recurrent VTE within 6 months. The RIETE-
VTE and the modified Ottawa score classified similar proportions of patients as low-risk 
(35.4% vs. 31.5%; P=0.37). No low-risk patient died within 30 days. Low-risk patients 
identified by the RIETE-VTE and modified Ottawa score had similar rates of overall 
complications (7.9% vs. 8.9%) and VTE recurrence (1.6% vs. 1.8%). The modified 
Ottawa score and the RIETE-VTE score had similar areas under the ROC curve for 
predicting all-cause mortality (0.84 vs. 0.75; P=0.21), overall complications (0.74 vs. 0.68; 
P=0.26), and VTE recurrence (0.67 vs. 0.64; P=0.78).
Conclusions: Both the RIETE-VTE and modified Ottawa score accurately identified 
elderly patients with CAT who are at low-risk for short-term mortality and who are 
potential candidates for outpatient care.
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Background
Cancer-associated venous thromboembolism (CAT) carries a high risk of mortality, 
recurrence, and bleeding [1, 2]. Given the often limited life expectancy of patients with 
CAT, treatment at home rather than in the hospital may be preferable [3]. However, 
cancer is the most common comorbidity that results in hospitalization in patients with 
deep vein thrombosis (DVT) [4], and patients with CAT are less likely to be treated at 
home than those without cancer [5]. Moreover, the proportion of patients with CAT who 
receive outpatient care is highly variable [5-8]. For instance, despite the recommendation 
to treat DVT at home [9], the proportion of cancer-associated DVT treated as outpatients 
ranges from 30% to 83% [5, 6, 8], indicating physicians’ insecurity whether patients with 
CAT can be safely managed at home.
Short-term prognosis in patients with CAT is influenced by multiple factors, 
including patient, tumor, and venous thromboembolism (VTE)-related characteristics, and 
treatments [10-12]. Thus, the identification of low-risk patients with CAT who are potential 
candidates for home care is challenging. To facilitate physician decision-making, several 
clinical risk assessment methods for CAT have been developed [13-17]. The modified 5-
item Ottawa score is the best validated risk assessment score for CAT and assigns 
patients with VTE (pulmonary embolism [PE] and DVT, including upper limb and unusual 
site thrombosis) into 3 risk categories of 6-month VTE recurrence [13]. Low-risk patients 
based on this score have a 6-month recurrence risk of 2.2% and a low 30-day overall 
mortality of <5% [18, 19]. Using data from the Registro Informatizado de la Enfermedad 
Thrombo-Embolica (RIETE), a 6-item score that classifies patients with CAT into 3 
classes of increasing 30-day all-cause mortality has been recently developed [10]. In the 
derivation and internal validation sample, low-risk patients based on the RIETE-VTE 
score had a 30-day mortality of 3.4% and 3.9%, respectively [10]. While the RIETE-VTE 
score showed a promising prognostic accuracy, it has not been independently validated. 
We aimed to externally validate the prognostic performance of the RIETE-VTE score in a 
prospective cohort of elderly patients with CAT and to compare it to the modified Ottawa 
score. We specifically focused on the scores’ ability to identify low-risk patients who may 
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Methods
Patients sample
This study is a post-hoc analysis of a prospective multicenter cohort study, which 
was conducted between September 2009 and December 2013 to assess long-term 
outcomes of elderly patients with acute, objectively confirmed, symptomatic VTE from 9 
Swiss hospitals [20]. VTE was defined as the presence of proximal or distal lower limb 
DVT or PE. Patients with isolated distal DVT were included only if the incompressible 
distal vein diameter was at least 5 mm. The institutional review board of all participating 
study sites approved all study procedures. We obtained informed consent from all 
participating patients. The study population and methods were described previously [20]. 
For the present study, we included only patients with a concomitant active solid or 
hematologic cancer defined as cancer that required active therapy (surgery, 
chemotherapy, radiotherapy, and/or palliative care) during the past 3 months before the 
index VTE. Local skin tumors such as basal cell carcinomas and spinal cell carcinomas 
were not considered as active cancer. All enrolled patients had a life expectancy of at 
least 3 months.
Patient baseline assessment
Trained research nurses prospectively collected baseline demographic information 
(age, sex, and body mass index [BMI]), type of the index VTE (PE or DVT), tumor history 
and treatment (primary site, presence of metastasis, recent chemotherapy, and cancer 
surgery), relevant clinical parameters (vital signs, heart failure, chronic lung disease, 
immobilization, and history of previous VTE), laboratory findings (leucocyte and platelet 
counts), and type of anticoagulation (low-molecular-weight heparin, unfractionated 
heparin, fondaparinux, and vitamin K antagonists), and the site of care for all enrolled 
patients. Data were recorded on standardized data collecting forms.
Patient outcomes assessment
The primary study outcome was all-cause mortality at 30 days. Secondary 
outcomes were overall complications at 90 days (mortality, recurrent VTE, or major 
bleeding), and VTE recurrence at 6 months after the index VTE. We defined recurrent PE 









This article is protected by copyright. All rights reserved
tomography, a cut-off of contrast in a vessel more than 2.5 mm in diameter on pulmonary 
angiography, a new perfusion defect involving 75% or more of a lung segment with 
corresponding normal ventilation (i.e., high probability lung scan) or confirmation of a new 
PE on autopsy [21, 22]. Diagnostic criteria for recurrent DVT were the non-compressibility 
of a new venous segment or a substantial increase (4 mm) in the diameter of the 
thrombus during full compression in a previously abnormal segment on ultrasonography 
or a new intraluminal filling defect on contrast venography [21, 22]. We defined major 
bleeding as a fatal bleeding, a bleeding with a reduction of hemoglobin of 20g/l or 
resulting in transfusion of 2 units of packed red blood cells or a symptomatic bleeding at 
critical sites (i.e., intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, 
pericardial, or intramuscular with compartment syndrome) [23].
We assessed all outcomes at a clinic visit after 90 days and via telephone 
interview 6 months after the index VTE. Trained study nurses interviewed patients during 
each visit/contact to obtain information about the date and type of clinical events (death, 
recurrent VTE, and bleeding). If a clinical event occurred, we complemented this 
information by reviewing medical charts and interviewing patients’ family members and 
primary care physicians. A committee of 3 independent, blinded clinical experts 
adjudicated all outcomes and classified the cause of all deaths as definitely or possibly 
due to PE, cancer, major bleeding, or another cause. Death was judged to be a definite, 
fatal PE if it was confirmed by autopsy, or if death followed a clinically severe PE, either 
initially or after an objectively confirmed recurrent event. Death was classified as possible 
fatal PE in a patient who died suddenly or unexpectedly. Death was considered to be 
bleeding related if it followed a bleeding episode leading to hemodynamic deterioration, 
or an intracranial hemorrhage. Final classifications were made based on the full 
consensus of this committee.
Risk assessment scores
Based on patient baseline demographical, clinical, and laboratory data obtained by 
chart review, we determined the presence of the 6 RIETE-VTE score risk factors and all 5 
individual risk factors comprising the modified Ottawa score (Table 1). For the RIETE-
VTE score, “immobility” is defined as ≥4 days of bed rest within the last 2 months before 
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immobility as bed rest for >72 hours, voyage in sitting position for >6 hours, or fracture or 
cast of the lower extremity in the past 3 months prior to the index VTE. For the modified 
Ottawa score, patients without metastasis were assumed to have a TNM stage I or II, as 
done in prior validation studies [19, 24, 25]. For the variables constituting the RIETE-VTE 
and modified Ottawa score, missing values were assumed to be normal. This strategy is 
widely used in the clinical application of prognostic models [26, 27]. All enrolled patients 
were then assigned to 3 risk classes (low, intermediate, high) based on the prognostic 
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Statistical analysis
We described the proportion of patients who were classified as low, intermediate, 
and high risk for 30-day all-cause mortality, 90-day overall complications, and 6-month 
VTE recurrence by RIETE-VTE and modified Ottawa score risk classes. Based on 
commonly accepted definitions of low-risk patients (RIETE-VTE score of ≤3; modified 
Ottawa score of ≤-1), we compared the proportion of patients classified as low-risk by the 
2 scores using McNemar’s test [28].
To determine the accuracy of each dichotomized score to predict 30-day all-cause 
mortality, 90-day overall complications, and 6-month VTE recurrence, we estimated 
sensitivity, specificity, and positive and negative predictive values and likelihood ratios for 
low- versus intermediate/high risk patients. We compared the discriminative power of 
each continuous score to predict 30-day all-cause mortality, 90-day overall complications, 
and 6-month VTE recurrence by calculating the area under the receiver operating 
characteristic (ROC) curve and a non-parametric test of the equality. We determined the 
goodness-of-fit of each score using logistic regression and the Pearson chi-square test. 
Because patients with isolated distal DVT were not included in the derivation sample of 
the Ottawa score [13], we performed a sensitivity analysis by excluding all patients with 
an isolated distal DVT. All analyses were done using STATA 15 (Stata Corporation, 
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Results
Study sample and comparison of outcomes
Of the 179 patients with CAT initially enrolled in our cohort study, one withdrew 
early from the study, leaving a final study population of 178 patients with CAT for our 
analysis. The patient baseline characteristics are shown in Table 2.
Overall, 15 patients (8.4%) died within 30 days (6 due to possible/definite PE, 5 
cancer, and 4 other causes, no death was bleeding-related), 7 (3.9%) had major 
bleeding, and 2 recurrent VTE (1.1%). Within 90 days, 42 patients (23.6%) had an overall 
complication (Table 3). Of these, 27 (15.2%) died (6 due to possible/definite PE, 17 
cancer, and 4 other causes, no death was bleeding-related), 13 (7.3%) had major 
bleeding, and 4 (2.2%) recurrent VTE (4 PE, 2 of which were fatal). After 6 months of 
follow-up, 6 patients (3.4%) suffered a recurrent VTE event (5 PE [2 fatal], 1 proximal 
DVT) (Table 3).
The RIETE-VTE and the modified Ottawa score classified similar proportions of 
patients as low-risk (35.4% vs. 31.5%; P=0.37), and none of the low-risk patients based 
on either score died within 30 days (Table 3). Among the RIETE-VTE intermediate risk 
patients, 30-day mortality was lower than among the intermediate-risk patients based on 
the modified Ottawa score (1.8% vs. 9.7%). Low-risk patients identified by the RIETE-
VTE score had similar rates of 90-day overall complications (7.9% vs. 8.9%) and 6-month 
VTE recurrence (1.6% vs. 1.8%) as low-risk patients based on the modified Ottawa 
score. High-risk patients based on the RIETE-VTE score had a higher 30-day all-cause 
mortality than high-risk patients based on the modified Ottawa score (23.7% vs. 16.0%) 
(Table 3) and similar 90-day overall complications (44.1% vs. 38.0%) and 6-month VTE 
recurrence rates (5.1% vs. 6.0%). After exclusion of the 17 patients with isolated distal 
DVT, the results did not change markedly (results not shown).
Comparison of predictive accuracy, discriminative power, and goodness-of-fit
When dichotomized as low- vs. intermediate/high risk, both scores were more 
accurate in predicting 30-day all-cause mortality than in predicting 90-day overall 
complications and 6-month VTE recurrence (Table 4). Both scores showed a 100% 
sensitivity, a 100% negative predictive value, and excellent negative likelihood ratios 
(<0.1) for predicting 30-day all-cause mortality (Table 4). The area under the ROC curve 
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modified Ottawa score (0.84, 95% confidence interval [CI] 0.77-0.89 vs. 0.75, 95% CI 
0.68-0.81; P=0.21) (Figure Panel A).
Both scores were less accurate at predicting 90-day overall complications and 6-
month VTE recurrence (Table 4). When dichotomized as low- vs. intermediate/high risk, 
the negative likelihood ratio for 90-day complications was 0.28 for the RIETE-VTE and 
0.32 for the modified Ottawa score. For 6-month recurrence, the negative likelihood ratio 
was 0.46 for the RIETE-VTE and 0.52 for the modified Ottawa score (Table 4). The 
RIETE-VTE and modified Ottawa score had a similar discriminatory power for predicting 
90-day overall complications (area under the ROC curve of 0.74 [95% CI 0.67-0.80] vs. 
0.68 [95% CI 0.61-0.75]; Figure Panel B) and 6-month VTE recurrence (area under the 
ROC curve of 0.67 [95% CI 0.60-0.74] vs. 0.64 [95% CI 0.57-0.71]; Figure Panel C). The 
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Discussion
Our prospective cohort study shows that the RIETE-VTE and the modified Ottawa 
score accurately identify patients with CAT who are at low risk for 30-day mortality. Both 
scores were less accurate in predicting 90-day overall complications and 6-month VTE 
recurrence. Given the differing prognosis of PE and DVT, it is debatable whether a 
prognostic score should cover both PE and DVT. However, in the case of CAT, a 
common prognostic score for PE and DVT may be justified by the fact that short-term 
mortality in CAT is mainly driven by non-VTE related causes (e.g., cancer progression) 
[29, 30] and that the risk of 90-day overall mortality following cancer-related DVT is high 
and not substantially lower than following cancer-related PE (19.4% vs. 24.5%) [31].
Although both scores were derived to allow for risk-based treatment strategies in 
patients with CAT, the scores differ in their methods. The Ottawa score was based on 
data of 543 patients from a single university hospital [13], whereas the RIETE-VTE score 
was derived using data from 6675 patients from a multicenter registry [10]. The RIETE 
investigators used recursive partitioning to identify candidate predictors from a broad set 
of variables, including age, sex, BMI, cancer-related factors, comorbid conditions, 
treatments, and laboratory parameters. The investigators from Ottawa used univariate 
analysis and a limited number of pre-defined predictors (sex, prior VTE, cancer-related 
factors, D-dimer level, and treatments). Of note, the Ottawa score originally used the 
exact TNM stage, but was modified by classifying patients into those without (TNM stage 
I/II) or with metastasis (TNM stage III/IV) [13]. Finally, the RIETE-VTE score was derived 
to predict 30-day all-cause mortality, whereas the derivation of the Ottawa score was 
based on 6-month recurrence. The differing methods resulted in 2 scores that share only 
one predictor (tumor stage).
When we compared both scores on a “level playing field” using prospective data 
from a multicenter cohort, both scores were excellent at identifying patients with CAT who 
have a low short-term mortality risk. Low and intermediate risk patients based on the 
RIETE-VTE and low risk patients based on the modified Ottawa score have a low 30-day 
overall mortality and are potential candidates for home care. The time spent at home in 
the last 6 months of life has been proposed as a quality indicator in oncology [3]. Home 
care may not only be preferred by many patients with CAT but is also more cost-effective 
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oral anticoagulants, which are recommended as a treatment option for patients with CAT 
who do not have a high risk of gastrointestinal or urogenital bleeding [33, 34]. In a recent 
study from a Dutch hospital two-thirds of outpatients with CAT were managed at home 
[8]. Overall, 13% of patients who received home care died from VTE or had recurrent 
VTE or major bleeding within 3 months compared to 19% of patients who were initially 
hospitalized [8].
It is important to note that the patient’s prognosis may not be the main determinant 
for choosing home care in CAT. Many high-risk patients with CAT who have a limited life 
expectancy may place a high value on quality of life and prefer to be managed at home. 
Outpatient management with close follow-up may be a reasonable option under such 
circumstances.
Somewhat paradoxically, the modified Ottawa score was more accurate at 
predicting 30-day all-cause mortality than 6-month VTE recurrence, the outcome for 
which it was originally derived. Given that the majority of patients with CAT die from 
cancer progression [10, 31], the major predictors that comprise the modified Ottawa 
score, cancer site and stage, may be even stronger predictors of mortality than of VTE 
recurrence. Both scores less accurately identified patients who had a low risk of medium-
term outcomes, i.e. 90-day complications and 6-month VTE recurrence.
In contrast to the modified Ottawa score, which incorporates clinical variables only, 
the RIETE-VTE score also comprises laboratory parameters. Leukocytosis, a marker for 
tumor inflammation [35], is associated with a 2-fold risk of recurrent VTE and a 3-fold risk 
of short-term mortality in patients with CAT [36]. Cancer-related thrombocytopenia may 
be caused by a direct cancer effect, treatments, and immune and microangiopathic 
disorders [37]. Besides being related with an increased bleeding risk [38], it is associated 
with a 2-fold higher risk of VTE recurrence [10].
Although our patients were older than those in the original derivation and validation 
samples of the RIETE-VTE and modified Ottawa score, they were less likely to be female 
(38% vs. 47% and 56%, respectively) and to have lung (12% vs. 17% and 18%, 
respectively) and metastatic cancer (40% vs. 62% and 66%, respectively) [10, 13]. As a 
result, both scores classified not only a higher proportion of patients as low-risk in our 
cohort than in the original derivation and validation samples (35% vs. 27% for the RIETE-
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day mortality than in the original RIETE derivation (8.4% vs. 12.5%) and a lower 6-month 
recurrence rate than in the Ottawa external validation sample (3.4% vs. 10.5%) [10, 13]. 
Thus, in our cohort, low-risk patients based on the RIETE-VTE score had a lower 30-day 
mortality risk than in the RIETE (0% vs. 3.4%) and low-risk patients based on the 
modified Ottawa score had a lower 6-month recurrence risk than in the Ottawa sample 
(1.8% vs. 5.1%) [10, 13].
This study is the first external validation of the RIETE-VTE score and has several 
strengths, including the enrolment of patients from diverse hospitals and a near complete 
prospective data collection. Our study has also limitations. First, our sample included 
older patients with PE or leg DVT and thus, our results may not be generalizable to 
younger patients or those with upper limb or unusual site thrombosis. Second, as our 
original cohort excluded patients with terminal illness (i.e., life expectancy <3 months), 
the most severely ill patients with CAT are not represented in our sample. Third, the 
sample size was relatively small and the power to detect statistically significant outcome 
differences may be limited. Fourth, our study was performed before the wide use of direct 
oral anticoagulants and immunotherapy as well as targeted therapy in cancer patients 
and thus, our results may not be applicable to patients who received such treatments. 
Finally, we aimed to compare clinical prognostic models for overall VTE and therefore did 
not evaluate PE-specific models for CAT (e.g., the POMPE-C tool) or outpatient 
treatment (e.g., HESTIA criteria) [39, 40].
In conclusion, this independent validation study demonstrates that both the RIETE-
VTE and the modified Ottawa score accurately identify low-risk patients with CAT who 
are potential candidates for home care. However, before the use of these scores can be 
recommended in clinical practice, their safety, efficacy, and positive impact on patient 
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Figure Legends
Figure
Panel A. Receiver-operating characteristics curves for 30-day all-cause mortality.
The areas under the receiver-operating characteristics curves were 0.84 (95% 
confidence interval [CI] 0.77-0.89) for the RIETE-VTE and 0.75 (95% CI 0.68-0.81) for 
the modified Ottawa score (P=0.21).
Panel B. Receiver-operating characteristics curves for 90-day overall complications.
The areas under the receiver-operating characteristics curves were 0.74 (95% 
confidence interval [CI] 0.67-0.80) for the RIETE-VTE and 0.68 (95% CI 0.61-0.75) for 
the modified Ottawa score (P=0.26).
Panel C. Receiver-operating characteristics curves for 6-month VTE recurrence.
The areas under the receiver-operating characteristics curves were 0.67 (95% 
confidence interval [CI] 0.60-0.74) for the RIETE-VTE and 0.64 (95% CI 0.57-0.71) for 
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Table 1 The modified Ottawa and RIETE-VTE scores
Risk assessment model Variables (points assigned) Risk stratification (cut-off points)
Modified Ottawa Score Female sex (1) Low (≤-1)
Lung cancer (1) Intermediate (0)
Breast cancer (-1) High (≥1)
TNM stage I or II (-1)
Previous VTE (1)
RIETE-VTE score Leukocytes ≥11.5 G/l (4) Low (0-3)
Metastasis (3) Intermediate (4-6)
Immobility*(3) High (≥7)
Body mass index <18.5 kg/m2 (3)
Any pulmonary embolism (2)
Platelets ≤160 G/l (2)
Abbreviations: TNM, tumor node metastasis; VTE, venous thromboembolism.
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Characteristic* n (%) or median (interquartile range)
Age, years 74 (69-80)
Male sex 110 (62)
Body mass index <18.5 kg/m2 6 (3)
Type of index venous thromboembolism
  Deep vein thrombosis only 61 (34)
  Pulmonary embolism only 96 (54)
  Deep vein thrombosis and pulmonary embolism 21 (12)
Primary cancer site
  Biliary system 2 (1)
  Bladder 7 (4)
  Brain 5 (3)
  Breast 16 (9)
  Cervix 2 (1)
  Colorectal 14 (8)
  Esophagus 5 (3)
  Hematological 20 (11)
  Kidney 6 (3)
  Liver 2 (1)
  Lung 22 (12)
  Musculoskeletal 3 (2)
  Ovary 5 (3)
  Pancreas 6 (3)
  Prostate 40 (22)
  Skin 4 (2)
  Stomach 2 (1)
  Other/unknown 17 (10)
Metastasis 72 (40)
Chemotherapy† 59 (33)
Cancer surgery† 30 (17)
Immobilization†‡ 57 (32)
Prior venous thromboembolism 37 (21)
History of heart failure 18 (10)
History of chronic lung disease 25 (14)
Systolic blood pressure <100mmHg 6 (3)
Leukocytes ≥11.5 G/l 47 (26)
Platelet count ≤160 G/l 46 (26)
Type of initial parenteral anticoagulation
  Low-molecular-weight heparin 86 (48)
  Unfractionated heparin 70 (39)
  Fondaparinux 17 (10)









Table 2 Patient baseline characteristics (n=178)
(cont.)
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(cont.)
Characteristic* n (%) or median (interquartile range)
Treatment with vitamin K antagonists 91 (51)
Outpatient management 31 (17)
*Data were missing for body mass index in 1% (n=1), chemotherapy in 1% (n=1), metastasis in 1% (n=1), 
systolic blood pressure in 2% (n=3), leucocyte count in 1% (n=2), and platelet count in 1% of patients (n=2).
†During the last 3 months.
‡Defined as bed rest for >72 hours, voyage in sitting position for >6 hours or fracture or cast of the lower 
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Table 3 Risk classification and clinical outcomes by risk class
 Low risk Intermediate risk High risk
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)
Risk classification
   RIETE-VTE score 63/178 35.4 (28.7-42.7) 56/178 31.5 (25.1-38.6) 59/178 33.2 (26.7-40.4)
   Modified Ottawa score 56/178 31.5 (25.1-38.6) 72/178 40.5 (33.5-47.8) 50/178 28.1 (22.0-35.1)
30-day all-cause mortality
   RIETE-VTE score 0/63 0.0 (0.0-5.8) 1/56 1.8 (0.3-9.5) 14/59 23.7 (14.7-36.0)
   Modified Ottawa score 0/56 0.0 (0.0-6.4) 7/72 9.7 (4.8-18.7) 8/50 16.0 (8.3-28.5)
90-day overall complications*  
   RIETE-VTE score 5/63 7.9 (3.4-17.3) 11/56 19.6 (11.3-31.8) 26/59 44.1 (32.2-56.7)
   Modified Ottawa score 5/56 8.9 (3.9-19.3) 18/72 25.0 (16.4-36.1) 19/50 38.0 (25.9-51.9)
6-month VTE recurrence
   RIETE-VTE score 1/63 1.6 (0.3-8.5) 2/56 3.6 (1.0-12.1) 3/59 5.1 (1.7-13.9)
   Modified Ottawa score 1/56 1.8 (0.3-9.5) 2/72 2.8 (0.8-9.6) 3/50 6.0 (2.1-16.2)
Abbreviation: CI, confidence interval; VTE, venous thromboembolism.
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Table 4 Accuracy to predict clinical outcomes in low- versus intermediate/high-risk patient
 




Positive PV, % (95% 
CI)







RIETE-VTE score 100.0 (79.6-100.0) 38.7 (31.5-46.3) 13.0 (8.1-20.4) 100.0 (94.3-100.0) 1.63 (1.44-1.84) 0.08 (0.01-1.24)*
Modified Ottawa score 100.0 (79.6-100.0) 34.4 (27.5-41.9) 12.3 (7.6-19.3) 100.0 (93.6-100.0) 1.52 (1.36-1.70) 0.09 (0.01-1.40)*
90-day overall complications†
RIETE-VTE score 88.1 (75.0-94.8) 42.6 (34.6-51.0) 32.2 (24.3-41.2) 92.1 (82.7-96.6) 1.54 (1.28-1.84) 0.28 (0.12-0.65)
Modified Ottawa score 88.1 (75.0-94.8) 37.5 (29.8-45.9) 30.3 (22.9-39.0) 91.1 (80.7-96.1) 1.41 (1.19-1.67) 0.32 (0.14-0.74)
6-month VTE recurrence
RIETE-VTE score 83.3 (43.6-97.0) 36.0 (29.2-43.5) 4.3 (1.9-9.8) 98.4 (91.5-99.7) 1.30 (0.90-1.90) 0.46 (0.08-2.80)
Modified Ottawa score 83.3 (43.6-97.0) 32.0 (25.5-39.3) 4.1 (1.8-9.2) 98.2 (90.6-99.7) 1.23 (0.84-1.78) 0.52 (0.09-3.16)
Abbreviations: CI, confidence interval; PV, predictive value; LHR, likelihood ratio; VTE, venous thromboembolism.
*Computed using the continuity correction
†Defined as death, recurrent venous thromboembolism, or major bleeding.
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